Imara reports third quarter 2021 financial results and business highlights

Interim analysis data for phase 2b clinical trials of tovinontrine (imr-687) in patients with beta-thalassemia and sickle cell disease expected in fourth quarter of 2021

ELVN Ratings Summary

ELVN Quant Ranking